<DOC>
	<DOCNO>NCT02008773</DOCNO>
	<brief_summary>The primary aim study determine efficacy adjunctive valacyclovir , comparison placebo , improve visual ( Brief Visuospatial Memory Test ) work ( composite score Spatial Span Letter Number Span test ) memory individual HSV-1 positive early course schizophrenia . We hypothesize individual HSV-1 positive , HSV-1 negative , demonstrate significant valacyclovir efficacy visual work memory .</brief_summary>
	<brief_title>A Double-Blind Trial Adjunctive Valacyclovir Improve Cognition Early Phase Schizophrenia</brief_title>
	<detailed_description>One hundred seventy-five participant ( N=70 HSV-1 seropositive N=105 HSV-1 seronegative ) randomize 1:1 receive adjunctive valacyclovir adjunctive placebo 16 week period . The primary outcome assess improvement change visual work memory score HSV-1 positive negative participant course study . We also measure overall cognitive functioning severity psychiatric symptom course study evaluate tolerability safety valacyclovir treatment population . In addition , explore relationship change level inflammatory marker ( HSV2 , CMV , EBV , CRP , Toxoplasmosis ) treatment response course study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>18 40 year age study entry . Able give write informed consent . DSM IVTR Diagnosis schizophrenia , schizophreniform , schizoaffective disorder confirm Structured Clinical Interview DSMIVTR ( SCID ) Onset schizophreniform disorder , schizophrenia , schizoaffective disorder within past eight year define first medical record documentation condition Outpatient inpatient . Clinical stability define : 1 . CGIS score less equal 4 ( moderately ill ) randomization AND 2 . Participants must experience exacerbation illness within 4 week prior randomization lead intensification psychiatric care opinion investigator . Examples intensification care include , limited : inpatient hospitalization , day/partial hospitalization , outpatient crisis management , psychiatric treatment emergency room AND 3 . Antipsychotic treatment stability least 4 week prior randomization ( change antipsychotic dosing , addition new antipsychotic medication , discontinue antipsychotic medication ) Fluent English . Female participant childbearing potential must test negative pregnancy screen visit agree use single , effective , medically acceptable method birth control duration study . Known IQ le 70 determined medical history . IV drug use within previous three month prior study entry . Any serious active medical condition affect brain cognitive functioning ( e.g. , epilepsy , serious head injury , brain tumor neurological disorder ) investigator 's opinion . Known medical history Human Immunodeficiency Virus ( HIV ) Receipt valacyclovir chemicallyrelated medication within 2 week prior randomization . History hypersensitivity valacyclovir acyclovir determine selfreport medical history . DSMIV diagnosis substance dependence within 3 month study entry ( exception nicotine caffeine dependence ) . Participants participate clinical trial pharmacological treatment intervention receive studyrelated medication 4 week prior screen AND participant currently receive treatment ( within 1 dose interval plus 4 week ) investigational depot formulation antipsychotic medication . Females pregnant planning become pregnant breastfeed planning study period . Participants current acute , serious , unstable medical condition , include , limited : inadequately control diabetes , asthma , COPD , recent cerebrovascular accident , acute systemic infection immunologic disease , unstable cardiovascular disorder , malnutrition , hepatic renal disease , renal include renal failure , gastroenterologic , respiratory , endocrinologic , neurologic , hematologic include thrombotic thrombocytopenia purpura/hemolytic uremic syndrome , infectious disease Participants require concomitant treatment medication allow specified Attachment 2 , medication specifically exclude Attachment 2 . Clinically significant electrocardiogram ( ECG ) abnormality prior randomization define : participant correct QT interval ( Bazett 's ; QTcB ) &gt; 450 msec ( male ) &gt; 470 msec ( female ) prior randomization . Repeat ECGs conduct discretion principal investigator medical designee . Test positive ( 1 ) Hepatitis C virus antibody , ( 2 ) Hepatitis B surface antigen ( HBsAg ) without positive Hepatitis B core total antibody . Participants moderate severe renal impairment define creatinine clearance ( CrCl ) &lt; 60 ml/min ( measure CockcroftGault equation ) screening . Participants hepatic impairment define liver transaminase total bilirubin &gt; 3 Ã— upper limit normal ( ULN ) . Participants consider high risk suicidal act active suicidal ideation determine clinical interview OR suicide attempt 90 day prior screen . Participants demonstrate overtly aggressive behavior deem pose homicidal risk investigator 's opinion . Participants currently receive cognitive remediation therapy time study entry Participants electroconvulsive therapy ( ECT ) within 12 month study entry ECT time study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>schizoaffective</keyword>
	<keyword>schizophreniform</keyword>
	<keyword>inflammatory marker</keyword>
	<keyword>HSV1</keyword>
	<keyword>cognition</keyword>
	<keyword>early psychosis</keyword>
	<keyword>valacyclovir</keyword>
</DOC>